leadf
logo-loader
viewAdvanced Oncotherapy PLC

Advanced Oncotherapy hires director with 35-year track record of “commercialising disruptive med-tech”

As the founder of MindSpan Consulting, Lori Cross’ client base includes Thermo Fisher Scientific, Medtronic, Nestle Healthcare, Danaher Beckman, GE Healthcare, and Novartis

Advanced Oncotherapy PLC -

Advanced Oncotherapy PLC (LON:AVO) is appointing a new independent director with a 35-year track record of “commercialising disruptive med-tech”.

As the founder of MindSpan Consulting, Lori Cross’ client base includes Thermo Fisher Scientific, Medtronic, Nestle Healthcare, Danaher Beckman, GE Healthcare, and Novartis.

Meanwhile, her experience working at companies such as VIASYS Healthcare, Smith & Nephew, and Baxter Edwards Laboratories will be invaluable in her new role helping guide a team rolling out the next-generation proton therapy systems for cancer treatment.

“Lori brings over 35 years of experience in commercialising disruptive MedTech innovations and her expertise will be invaluable to our business as we continue to progress the LIGHT system and develop commercial partnerships,” said Advanced Oncotherapy chairman, Dr Mike Sinclair.

Quick facts: Advanced Oncotherapy PLC

Price: 30.5 GBX

LSE:AVO
Market: LSE
Market Cap: £93.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Advanced Oncotherapy PLC named herein, including the promotion by the Company of Advanced Oncotherapy PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read